Tissue expression, serum and salivary levels of IL-10 in patients with head and necksquamous cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 1681-1685

  Hamzavi, Marzieh ^a   Tadbir, Azadeh Andisheh ^a   Rezvani, Gita ^a   Ashraf, Mohammad Javad ^b   Fattahi, Mohammad Javad ^c   Khademi, Bijan ^a   Sardari, Yasaman ^a   Jeirudi, Naghmeh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

10; Head and neck SCC; Interleukin; Saliva; Serum

Indexed keywords

EID: 84880431998     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.1681     Document Type: Article

References (22)

1. Alhamarneh O, Agada F, Madden L, et al (2010). Serum IL-10 and Circulating CD4+CD25inch regulatory T cell numvers aspredictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck, 10, 415-23.
2. Asadullah S, Sterry W, Volk HD (2003). Interleukin-10 Therapy-Review of a new Approch. Pharmacol Rev, 55, 241-69.
3. Berman RM, Suzuki T, Tahara H, et al (1996). Systemic administration of cellular IL-10 induces an effective, specific c, and long-lived immune response against established tymors in mice. J Immunol, 157, 231-8.
4. Berzofsky JA, Terabe M (2009). The contrasing roles of NKT cells in tumor immunity. Curr Mol Med, 9, 667-72.
5. Brooks M, Wang J, Li Y, et al (2008). Salivary protein factors are elevated in breast cancer patients. Nip Publish Access Author Manuscript, 1, 75-378.
6. Cervenak L, Morbidelli L, Donati D, et al (2000). Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by Interleukin-10. Blood, 96, 2568-73.
7. Chandler S, Rassekh C, Roadman S, et al (2002). Immunohistochemical localization of Interleukin-10 in human oral and pharyngeal carcinoma. Laryngoscope, 112, 808-15
8. DiLillo DJ, Matsushita T, Tedder TF (2010). B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci, 1183, 38-57.
9. Fujieda SH, Sunaga H, Tsuzuki H, et al (1999). IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Letter, 136, 1-9.
10. Hoffmann TK, Sonkoly E, Homey B (2007). Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck, 29, 472-8.
11. Lathers DM, Young MR (2004). Increased aberrance of cytokine expression in plasma of patient with more advanced squamous cell carcinoma of the head and neck. Cytokine, 25, 220-8.
12. Linkov F, Lisovich A, Yurkovetsky Z (2007). Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev, 16, 102-7.
13. Liu J, Song B, Wang JL, et al (2011). Polymorphisms of Interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol, 17, 1362-7
14. Nelson EL, Wenzel LB, Osann K, et al (2008) Stress, immunity and cervical cancer: biobehavioral outcomes of a randomized clinical trial. Clin Cancer Res, 14, 2111-8.
15. Sabat R, Grutz G, Warszawska K, et al (2010). Biology of interleukin-10. Cytokine Growth factor REV, 21, 331-44.
16. Shang ZJ, Li JR, Li ZB (2007). Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofact Surg, 65, 17-21.
17. Sparano A, Lathers DM, Achille N, et al (2004). Modulation of TH1 and TH2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg, 131, 573-6.
18. Stearns ME, Rhim J, Wang M (1999). Interleukin-10 (IL-10) inhibition of primary human prostate cellinduced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res, 5, 189-96.
19. Teles RP, Likhari V, Socransky SS, et al (2009). Salivary cytokine levels in chronic periodontitis and periodomtally healthy subjects. A cross-sectional study. J Periodontal Res, 44, 411-7.
20. Toiyama Y, Miki C, Inoue Y, et al (2010). Loss of tissue expression of IL-10 promotes the disease progression of colorectal carcinoma. Surg Today, 46, 46-53.
21. Wozniak KL, Arribas A, Leigh JE, et al (2002). Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol, 17, 100-7.
22. Zheng LM, Ojcius DM, Garaud F, et al (1996). Interleukin-10 inhibits tumor metastasis through an NK cell dependent mechanism. J Exp Med, 184, 579-84.